× Business BUSINESS MOTORING SHIPPING & LOGISTICS DR PESA FINANCIAL STANDARD Digital News Videos Health & Science Lifestyle Opinion Education Columnists Moi Cabinets Arts & Culture Fact Check Podcasts E-Paper Lifestyle & Entertainment Nairobian Entertainment Eve Woman Travelog TV Stations KTN Home KTN News BTV KTN Farmers TV Radio Stations Radio Maisha Spice FM Vybez Radio Enterprise VAS E-Learning Digger Classified Jobs Games Crosswords Sudoku The Standard Group Corporate Contact Us Rate Card Vacancies DCX O.M Portal Corporate Email RMS

AstraZeneca to buy Alexion for $39 billion to expand in immunology

By Reuters | December 14th 2020
Brazilian pediatric doctor Monica Levi, one of the volunteers who received the COVID-19 vaccine in Sao Paulo, Brazil. [AFP]

Britain’s AstraZeneca has agreed to buy US drugmaker Alexion Pharmaceuticals for Sh40 billion ($39 billion) in its largest ever deal, diversifying from its cancer business in a bet on rare-disease and immunology drugs.

The deal comes in a week that AstraZeneca said it was conducting further research to confirm whether its Covid-19 vaccine could be 90 per cent effective as a rival shot from Pfizer was launched in Britain and approved for use in the US.


Share this story
Creditor seeks winding up of Buzeki’s business empire
The firm filed a bankruptcy petition against Buzeki Enterprises Ltd at the High Court's commercial and tax division.
Dog walking becomes the newest hustle in town
Dog walking is now a status symbol. Owning a pet is cool. I nowadays meet lots of Kenyans and foreigners walking their dogs and some running.